Epizyme Inc (EPZM)

18.70
NASDAQ : Health Care
Prev Close 18.70
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.38 / 20.00
Avg Volume 552.60K
Exchange NASDAQ
Shares Outstanding 58.61M
Market Cap 1.13B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics and Epizyme are raising cash to fund new drug development.

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported.

US Oncology Research And Epizyme Establish Collaboration To Identify Non-Hodgkin Lymphoma Patients With EZH2 Mutations

US Oncology Research And Epizyme Establish Collaboration To Identify Non-Hodgkin Lymphoma Patients With EZH2 Mutations

Eligible Patients to be Directed to Epizyme's Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Biotech Movers: Sangamo, Epizyme, Revance

Biotech Movers: Sangamo, Epizyme, Revance

Sangamo Therapeutics, Epizyme and Revance were among the biotech stock movers in premarket trading on June 21.

First Week of EPZM February 2018 Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the February 2018 expiration.

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.

First Week of July 21st Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options become available this week, for the July 21st expiration.

Epizyme Announces Date Of First Quarter 2017 Financial Results And Tazemetostat Data Presentations At ASCO

Management to Host Conference Call on May 18, 2017 at 8:30 a.m. ET

Epizyme President Of Research And Chief Scientific Officer, Robert Copeland, Announces Retirement From The Company

Dr. Copeland to Remain a Key Advisor to Epizyme Following Transition

TheStreet Quant Rating: D (Sell)